Executives at the British drug maker GlaxoSmithKline were warned nearly two years ago about critical problems with the way the company conducted research at its drug development center in China, exposing it to potential financial risk and regulatory action, an internal audit found. Eric G. Campbell, HMS professor of medicine at Massachusetts General Hospital and Jerry Avorn, HMS professor of medicine at Brigham and Women’s Hospital, are quoted.
